drugset / Trial / NCT00479635
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TPI 287 | Small molecule | 160 mg/m2 | Intravenous |